ThromboGenics NV - Product Pipeline Review - 2015

Date: June 24, 2015
Pages: 33
Price:
US$ 1,500.00 US$ 1,200.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: T1998F720D0EN
Leaflet:

Download PDF Leaflet

ThromboGenics NV - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘ThromboGenics NV - Product Pipeline Review - 2015’, provides an overview of the ThromboGenics NV’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of ThromboGenics NV’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of ThromboGenics NV including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of ThromboGenics NV’s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the ThromboGenics NV’s pipeline products
Reasons to buy
  • Evaluate ThromboGenics NV’s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of ThromboGenics NV in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the ThromboGenics NV’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of ThromboGenics NV and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of ThromboGenics NV
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of ThromboGenics NV and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues
ThromboGenics NV Snapshot
ThromboGenics NV Overview
Key Information
Key Facts
ThromboGenics NV - Research and Development Overview
Key Therapeutic Areas
ThromboGenics NV - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Pipeline Products - Out-Licensed Products
Out-Licensed Products/Combination Treatment Modalities
ThromboGenics NV - Pipeline Products Glance
ThromboGenics NV - Late Stage Pipeline Products
Phase III Products/Combination Treatment Modalities
ThromboGenics NV - Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
ThromboGenics NV - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
ThromboGenics NV - Drug Profiles
ocriplasmin (recombinant)
Product Description
Mechanism of Action
R&D Progress
TG-758
Product Description
Mechanism of Action
R&D Progress
TG-931
Product Description
Mechanism of Action
R&D Progress
ThromboGenics NV - Pipeline Analysis
ThromboGenics NV - Pipeline Products by Target
ThromboGenics NV - Pipeline Products by Route of Administration
ThromboGenics NV - Pipeline Products by Molecule Type
ThromboGenics NV - Pipeline Products by Mechanism of Action
ThromboGenics NV - Recent Pipeline Updates
ThromboGenics NV - Dormant Projects
ThromboGenics NV - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

ThromboGenics NV, Key Information
ThromboGenics NV, Key Facts
ThromboGenics NV - Pipeline by Indication, 2015
ThromboGenics NV - Pipeline by Stage of Development, 2015
ThromboGenics NV - Monotherapy Products in Pipeline, 2015
ThromboGenics NV - Out-Licensed Products in Pipeline, 2015
ThromboGenics NV - Out-Licensed Products/ Combination Treatment Modalities, 2015
ThromboGenics NV - Phase III, 2015
ThromboGenics NV - Phase II, 2015
ThromboGenics NV - Phase I, 2015
ThromboGenics NV - Preclinical, 2015
ThromboGenics NV - Pipeline by Target, 2015
ThromboGenics NV - Pipeline by Route of Administration, 2015
ThromboGenics NV - Pipeline by Molecule Type, 2015
ThromboGenics NV - Pipeline Products by Mechanism of Action, 2015
ThromboGenics NV - Recent Pipeline Updates, 2015
ThromboGenics NV - Dormant Developmental Projects,2015
ThromboGenics NV, Other Locations
ThromboGenics NV, Subsidiaries

LIST OF FIGURES

ThromboGenics NV - Pipeline by Top 10 Indication, 2015
ThromboGenics NV - Pipeline by Stage of Development, 2015
ThromboGenics NV - Monotherapy Products in Pipeline, 2015
ThromboGenics NV - Pipeline by Top 10 Target, 2015
ThromboGenics NV - Pipeline by Top 10 Route of Administration, 2015
ThromboGenics NV - Pipeline by Top 10 Molecule Type, 2015
ThromboGenics NV - Pipeline Products by Top 10 Mechanism of Action, 2015
Skip to top


Ask Your Question

ThromboGenics NV - Product Pipeline Review - 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: